Ionophore reverses Alzheimer's within days in mouse models

Jul 09, 2008

Scientists report a remarkable improvement in Alzheimer's transgenic mice following treatment with a new drug. The study, published by Cell Press in the July 10th issue of the journal Neuron, provides the first demonstration that an ionophore, a compound that transports metal ions across cell membranes, can elicit rapid and pronounced improvement in neuropathology and cognitive function in mouse models of Alzheimer's Disease (AD).

Recent research has implicated dysregulation of metal ions in the brain, particularly copper and zinc, in the pathogenesis of AD and the damaging accumulation of amyloid beta (A?) protein that is characteristic of this devastating disease. The ionophore clioquinol (CQ), an 8-hydroxyquinoline, has been shown to increase intracellular copper and zinc levels and decrease A? levels in cultured cells and in the brains of transgenic (Tg) AD mice. However, further studies in mice and humans demonstrated that brain entry of CQ was quite limited.

Dr. Ashley I. Bush from the Mental Health Research Institute of Victoria in Australia, with Dr. Paul A. Adlard and colleagues examined the therapeutic potential of PBT2, a second generation 8-hydroxyquinoline designed for easier synthesis, higher solubility and increased blood-brain barrier permeability, in two well established Tg mouse models of AD. The Tg mice examined in the study overexpress the precursor protein for A? and possess mutations that cause AD in humans. One of the Tg models also expresses the human presenilin deletion mutation that also causes AD.

"Both types of Tg mice exhibit progressive spatial learning deficits that are accompanied by increasing A? levels and plaque formation. Demonstrating benefits of PBT2 treatment in the two separate models was both a stringency test, increasing confidence that PBT2 is more likely to show benefit in clinical trials, and also allowed us to determine whether specific forms of A? change in register with cognitive improvement in both strains. This is significant as cognitive loss in AD is not just a simple product of rising A? levels," explains Dr. Bush.

PBT2 was shown to be a superior ionophore when compared to CQ and the researchers went on to test A? levels and cognitive outcomes after oral treatment with PBT2. "We found that oral treatment with PBT2 induced a dramatic improvement in learning and memory in both Tg models of AD, accompanied by a marked inhibition of AD-like neuropathology. These outcomes were rapid, with reduction of soluble interstitial A? occurring within hours, and significant cognitive benefits seen within days of first administration of the compound," says Dr. Bush.

These results encourage further testing of compounds that target synaptic metals as a possible treatment of AD. Further, recent clinical trials in AD patients taking oral PBT2 have been promising and support PBT2 as a viable treatment for AD.

Source: Cell Press

Explore further: Mouth bacteria invade the gut in liver cirrhosis patients

add to favorites email to friend print save as pdf

Related Stories

How Kindle Unlimited compares with Scribd, Oyster

3 hours ago

Amazon is the latest—and largest—company to offer unlimited e-books for a monthly fee. Here's how Kindle Unlimited, which Amazon announced Friday, compares with rivals Scribd and Oyster.

NASA sees powerful thunderstorms in Tropical Storm Matmo

3 hours ago

Strong thunderstorms reaching toward the top of the troposphere circled Tropical Storm Matmo's center and appeared in a band of thunderstorms on the storm's southwestern quadrant. Infrared imagery from NASA's ...

ISS 'space truck' launch postponed: Arianespace

5 hours ago

The July 24 launch of a robot ship to deliver provisions to the International Space Station has been postponed "for a few days", space transport firm Arianespace said Friday.

Recommended for you

Experts call for stepped-up hepatitis battle

3 hours ago

The world can beat the cancer-causing disease hepatitis if it raises its game, but treatment programmes need to go hand in hand with those tackling the likes of HIV, experts said Thursday.

User comments : 0